Effect of Unani medicine Majoon Muqawwi Rahem in SayalÄ?n al-Rahim (Leucorrhoea)

Clinical Validation of Unani Pharmacopoeial formulation Majoon Muqawwi Rahem in SayalÄ?n al-Rahim (Leucorrhoea)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016191

Enrollment

300

Registered

2018-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N899- Noninflammatory disorder of vagina, unspecified Health Condition 2: null- SayalÄ?n al-Rahim (Leucorrhoea)

Interventions

Intervention1: Majoon Muqawwi Rahem: 5 grams orally twice daily after meals Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1.Female patients in the age group of 13-45 years. 2.Patients having excessive white discharge with or without any of the following associated symptoms 3.Wajaâ?? al-Zahr (Backache) 4.Naqahat (General Weakness)

Exclusion criteria

Exclusion criteria: 1.Patients having acute/ acute on chronic/Chronic PIDs (as per the CDC Diagnostic Criteria attached as an annexure-IV) 2.Patients with diseases requiring long-term treatment 3.Patients on Oral Contraceptives/IUDs • Patients taking hormonal therapy • Any abnormal condition on p/s Examination • Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of SayalÄ?n al-Rahim (Leucorrhoea)Timepoint: 2 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: Baseline and end of treatment	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026